Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 16/20 | 0.57 |
| ▸ | CASP1 | P29466 | 14/20 | 0.57 |
| ▸ | CASP7 | P55210 | 14/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 15/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 15/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 12/20 | 0.55 |
| ▸ | LMNA | P02545 | 8/20 | 0.55 |
| ▸ | BRCA1 | P38398 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.54 |
| ▸ | HBB | P68871 | 5/20 | 0.54 |
| ▸ | CDK4 | P11802 | 2/20 | 0.54 |
| ▸ | CCND1 | P24385 | 2/20 | 0.54 |
| ▸ | CCND2 | P30279 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518205 | 0.84 | CDK4 (0.63) | FGFR1USP2CASP1CASP7HIF1A | |
| SCHEMBL4710919 | 0.83 | FGFR1 (0.73) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Hydrochloric Acid SCHEMBL4712628 | 0.83 | FGFR1 (0.72) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4675633 | 0.80 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4208654 | 0.77 | FGFR1 (0.54) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4710509 | 0.74 | FGFR1 (0.64) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4712912 | 0.74 | FGFR1 (0.59) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4712645 | 0.73 | FGFR1 (0.65) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4712669 | 0.73 | FGFR1 (0.58) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4713077 | 0.71 | FGFR1 (0.56) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | claimed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | claimed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | claimed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | FGFR1 91/4885FGFR2 117/4885FGFR4 234/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | FGFR1 50/4885FGFR2 67/4885FGFR4 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.